Universe Pharmaceuticals Inc is a pharmaceutical company specializing in the manufacturing, marketing, sales and distribution of traditional Chinese medicine derivatives products targeting the elderly with the goal of addressing their physical conditions in the ageing process and promoting their general well-being... Show more
The 10-day RSI Oscillator for UPC moved out of overbought territory on December 29, 2025. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 16 instances where the indicator moved out of the overbought zone. In of the 16 cases the stock moved lower in the days that followed. This puts the odds of a move down at .
The Momentum Indicator moved below the 0 level on January 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on UPC as a result. In of 99 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The 50-day moving average for UPC moved below the 200-day moving average on December 24, 2025. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where UPC declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
UPC broke above its upper Bollinger Band on December 26, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for UPC just turned positive on December 24, 2025. Looking at past instances where UPC's MACD turned positive, the stock continued to rise in of 40 cases over the following month. The odds of a continued upward trend are .
UPC moved above its 50-day moving average on January 07, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for UPC crossed bullishly above the 50-day moving average on January 02, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 8 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a +5 3-day Advance, the price is estimated to grow further. Considering data from situations where UPC advanced for three days, in of 199 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 118 cases where UPC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.043) is normal, around the industry mean (29.656). P/E Ratio (0.000) is within average values for comparable stocks, (75.571). UPC's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.019). UPC has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.030). P/S Ratio (0.040) is also within normal values, averaging (72.365).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. UPC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. UPC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry PharmaceuticalsGeneric